Ending AIDS in Johannesburg : An Analysis of the Status and Scale-Up Towards HIV Treatment and Prevention Targets
Johannesburg, one of South Africa’s metropolitan municipalities and one of the 52 health districts has more people living with HIV (PLHIV) than any other city worldwide at ~600,000. This brief provides the key results of a modeling analysis estimat...
| Main Author: | |
|---|---|
| Format: | Brief |
| Language: | English en_US |
| Published: |
World Bank, Washington, DC
2016
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/990681479363259898/Ending-aids-in-Johannesburg-an-analysis-of-the-status-and-scale-up-towards-HIV-treatment-and-prevention-targets http://hdl.handle.net/10986/25685 |
| Summary: | Johannesburg, one of South Africa’s
metropolitan municipalities and one of the 52 health
districts has more people living with HIV (PLHIV) than any
other city worldwide at ~600,000. This brief provides the
key results of a modeling analysis estimating what it would
take in terms of programmatic targets and costs for
Johannesburg to meet the Fast-Track targets and demonstrate
the impact that this would have. The Optima HIV epidemic and
resource allocation model was used, distinguishing 26
sub-populations and populated with the available
demographic, epidemiological, behavioral, programmatic and
financial data. The analysis demonstrated that Johannesburg
has rapidly expanded HIV diagnosis and treatment between
2010 and 2015, reaching 267,236 PLHIV with the ART program
in 2015. In 2015, an estimated 70 percent knew about their
positive status, about 64 percent of diagnosed PLHIV
accessed treatment, and about 54 percent of them were known
to be virally suppressed. The analysis suggested that the
health impact of successfully scaling-up HIV testing,
treatment and ART adherence to the 2020 and 2030 Sustainable
Development Goals target levels is very large in
Johannesburg. The increase in PLHIV on treatment will result
in reductions in new HIV infections (an estimated cumulative
difference of ~327 thousand infections from 2016-30). It
will also results in reductions in HIV-related deaths (a
cumulative difference of ~104 thousand deaths from 2016-30). |
|---|